Clinical Resources

March 11, 2024—The American Society of Nuclear Cardiology (ASNC) and Heart Rhythm Society (HRS), in partnership with 9 other societies, have released a consensus statement on the use of PET/CT and SPECT/CT imaging in diagnosing cardiovascular infections. The document provides guidance on clinical scenarios of suspected infections from native and prosthetic heart valves, cardiovascular implantable electronic devices, prosthetic material, and ventricular assist devices.

November 30, 2023—The American College of Cardiology (ACC) and American Heart Association (AHA) released updated recommendations for preventing and managing atrial fibrillation. The new guideline was developed in collaboration with and and endorsed by the American College of Clinical Pharmacy (ACCP) and the Heart Rhythm Society (HRS).

May 20, 2023—The Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Latin American Heart Rhythm Society (LAHRS) have partnered to provide guidance on cardiac physiologic pacing strategies to restore ventricular synchrony and improve cardiac performance. This clinical practice guideline is a comprehensive resource with recommendations applicable to patients who have or are at risk of heart failure who are being considered for or who are undergoing a cardiac physiologic pacing implantation procedure.

May 19, 2023—The Heart Rhythm Society (HRS) released a new expert consensus statement on the management of cardiac arrhythmias during pregnancy. The document is a comprehensive resource with practical guidance on the optimal management of arrhythmias in pregnant patients and in fetuses.

May 19, 2023—The Heart Rhythm Society (HRS), European Heart Rhythm Association (EHRA), Asia Pacific Heart Rhythm Society (APHRS), and Latin American Heart Rhythm Society (LAHRS) have partnered to provide guidance on the management of remote device clinics.

October 27, 2022—The Heart Rhythm Society (HRS) released a revised policy statement on the role of industry-employed allied professionals. 

January 29, 2021—This ISHNE/HRS/EHRA/APHRS collaborative statement describes the current status of mobile health (mHealth) technologies in arrhythmia management. The range of digital medical tools and heart rhythm disorders that they may be applied to and clinical decisions that may be enabled are discussed. The facilitation of comorbidity and lifestyle management (increasingly recognized to play a role in heart rhythm disorders) and patient self-management are novel aspects of mHealth. The promises of predictive analytics but also operational challenges in embedding mHealth into routine clinical care are explored.

  The Russian and Spanish (Executive Summary) translations are available.

The Heart Rhythm Society endorsed the document on August 6, 2020.

December 7, 2020—There were two changes to the performance measures, both prompted by recent changes to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. The first, which impacts all the performance measures (see Appendix A, for the changes and measure specifications), is the clarification that valvular atrial fibrillation is atrial fibrillation with either moderate or severe mitral stenosis or a mechanical heart valve. The second change is the separation of a male and female threshold for the CHA₂DS₂-VASc score. This only applies to PM-5: Atrial Fibrillation/Atrial Flutter: Anticoagulation Prescribed.

The Heart Rhythm Society endorsed the document on August 19, 2020.

November 20, 2020—The purpose of this guideline is to commission a full guideline revision of the 2011 ACCF/ AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. This version replaces the 2011 guideline and addresses comprehensive evaluation and management of adults and children with hypertrophic cardiomyopathy. Diagnostic modalities such as electrocardiography, imaging and genetic testing, and management of patients include medical therapies, septal reduction therapies, sudden cardiac death risk assessment/prevention, and lifestyle considerations such as participation in activities/sports, occupation, and pregnancy.

October 19, 2020—This expert consensus statement, developed in partnership between the Asia Pacific Heart Rhythm Society (APHRS) and the Heart Rhythm Society (HRS) and in collaboration with the Association for European Cardiovascular Pathology (AECVP), the European Heart Rhythm Association (EHRA), the European Society of Human Genetics (ESHG), the Latin American Heart Rhythm Society (LAHRS), the National Society of Genetic Counselors (NSGC), the Pediatric and Congenital Electrophysiology Society (PACES), and the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart), provides a framework for the investigation of patients with sudden cardiac arrest (SCA), decedents with sudden unexplained death (SUD), and families of both SCA survivors and SUD victims. 

 The document features a slide set and a video interview on Heart Rhythm TV.